PMV Pharmaceuticals
PMVP
51 hedge funds and large institutions have $1.09B invested in PMV Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
72.59% more ownership
Funds ownership: 0% → 72.59% (+73%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$270M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
+$238M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$97.2M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$83.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$68.1M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Millennium Management
New York
| $9.96K | +$10.3M | +280,425 | New |
|
PMVP Hedge Fund Activity: Q3 2020 in Review
51 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2020, worth a combined $1.09B.
Buyers outnumbered sellers: 51 funds opened new PMVP positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $270M.
- 51 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $1.09B of PMV Pharmaceuticals stock for Q3 2020.
- 51 funds opened new PMV Pharmaceuticals positions in Q3 2020 and 0 closed out, a net change of +51 holders.
- The largest PMV Pharmaceuticals buyer in Q3 2020 was OrbiMed, an estimated $270M added.
Based on aggregated 13F filings for Q3 2020.